atazanavir- atazanavir capsule
camber pharmaceuticals, inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: • atazanavir are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [ see use in specific populations ( 8.4) ]. • use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [ see microbiology ( 12.4)] . atazanavir capsules are contraindicated: • in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens- johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [ see warnings and precautions (
reyataz capsule
bristol-myers squibb canada - atazanavir (atazanavir sulfate) - capsule - 150mg - atazanavir (atazanavir sulfate) 150mg - hiv protease inhibitors
teva-atazanavir capsule
teva canada limited - atazanavir (atazanavir sulfate) - capsule - 200mg - atazanavir (atazanavir sulfate) 200mg - hiv protease inhibitors
teva-atazanavir capsule
teva canada limited - atazanavir (atazanavir sulfate) - capsule - 300mg - atazanavir (atazanavir sulfate) 300mg - hiv protease inhibitors
apo-atazanavir capsule
apotex inc - atazanavir (atazanavir sulfate) - capsule - 200mg - atazanavir (atazanavir sulfate) 200mg - hiv protease inhibitors
apo-atazanavir capsule
apotex inc - atazanavir (atazanavir sulfate) - capsule - 300mg - atazanavir (atazanavir sulfate) 300mg - hiv protease inhibitors
atazanavir capsule
laurus labs limited - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years of age and older weighing at least 15 kg. limitations of use: - atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see use in specific populations (8.4)] . - use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir capsules are contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interact
cipla atazanavir atazanavir 150 mg capsule bottle pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
cipla atazanavir atazanavir 150 mg capsule blister pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
zanavir ca atazanavir 150 mg capsule bottle pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).